Peptide Legal Status in Europe: EMA Framework, Country Differences, and Access Routes

Europe presents one of the most fragmented regulatory landscapes for peptides. The European Medicines Agency (EMA) sets an overarching framework for medicines approval across EU member states, but the implementation of that framework—particularly for unlicensed and compounded medicines—varies significantly by country. A peptide that is accessible through a prescription in one EU country may be more difficult to obtain legally in another, and enforcement of research chemical sales differs dramatically across the continent.

The EMA Framework: Centralized Authorization

The EMA's centralized procedure grants marketing authorization valid across all 27 EU member states simultaneously. Many of the most widely-used therapeutic peptides have received EMA centralized authorization:

EMA-authorized peptides include GLP-1 receptor agonists (semaglutide as Ozempic and Wegovy, liraglutide as Victoza and Saxenda, dulaglutide as Trulicity), insulin formulations, oxytocin, desmopressin, terlipressin, and tesamorelin. These are legally available by prescription across the EU through licensed pharmacies.

The centralized authorization process applies to many high-priority medicines. However, many peptides of interest in the performance, longevity, and functional health community have not gone through the EMA process—either because the commercial incentive is insufficient, the research base is insufficient for approval, or because no company has chosen to pursue authorization.

The EU Off-Label and Compassionate Use Framework

Each EU member state maintains its own framework for accessing medicines outside of standard marketing authorizations. These mechanisms include:

Compassionate use programs: For serious or life-threatening conditions where no adequate treatment exists, individual member states can authorize access to unapproved medicines outside clinical trials.

Named-patient programs: Individual prescribers can request authorization to use an unlicensed medicine for a specific named patient when no licensed alternative is available.

Hospital exemptions: Some member states allow hospitals to prepare or source medicines outside the standard authorization framework for specific patient populations.

These mechanisms vary significantly in how practical they are for peptides used in longevity, sports medicine, or functional health contexts rather than acute disease. The named-patient pathway is the most relevant for routine peptide therapy in countries with strict controls.

Country-by-Country Overview

Germany

Germany operates under a relatively strict interpretation of the Medicinal Products Act (Arzneimittelgesetz, AMG). Key features:

• Prescription-only status applies to most therapeutic peptides
• German compounding pharmacies (Apotheken) can prepare magistral formulations under physician prescription using the prescription pathway
• The German approach to research chemical vendors has become more enforcement-focused, particularly following coordination with BtMG (Betäubungsmittelgesetz, the controlled substances law) for relevant compounds
• BPC-157, ipamorelin, and similar research peptides are not available OTC through German pharmacies; they require physician prescriptions for compounding
• The German Institute for Medicinal Products and Medical Devices (BfArM) oversees prescription medicine classification

Practically, German patients seeking compounded peptide therapy need physician prescriptions and must source through licensed compounding pharmacies. The research chemical market operates largely through foreign websites, which German customs can intercept.

Netherlands

The Netherlands has historically had a more permissive approach to gray-area substances than many EU neighbors, though this applies more clearly to controlled substances than to medicines. For peptides:

• The Medicines Act (Geneesmiddelenwet) requires marketing authorization for medicines sold in the Netherlands
• Dutch customs enforcement of research peptide imports has been variable
• Compounding (bereiden) is permitted in Dutch pharmacies under the supervision of a registered pharmacist
• Some Dutch physicians—particularly in the sports medicine and integrative health space—have been more willing to prescribe unlicensed peptide formulations than their counterparts in more restrictive EU countries
• The Netherlands is a significant European hub for pharmaceutical and research chemical logistics, which affects import and seizure patterns

Spain

Spain's regulations under the Ley 29/2006 de garantías y uso racional de los medicamentos (Law on Medicines) and the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) oversight create a prescription-required framework for therapeutic peptides:

• Magistral formulations (compounded medicines) are legal in Spain under physician prescription
• Spanish compounding pharmacies have regulatory flexibility to prepare peptide formulations not available as licensed medicines
• Online pharmacies operating in Spain must be AEMPS-registered; unlicensed foreign online pharmacies are not legally authorized to supply Spanish residents
• Research chemical imports face customs scrutiny; enforcement has intensified in collaboration with AEMPS as gray-market peptide sales grew
• Some Spanish clinics in the anti-aging and functional medicine space offer prescription-based peptide therapy

France

France's ANSM (Agence nationale de sécurité du médicament) takes a notably strict approach:

• Prescription requirements are enforced strictly for therapeutic peptides
• Compounding (préparations magistrales) is permitted but tightly regulated; quality control requirements are stringent
• Research chemical sales targeting French consumers have faced enforcement actions
• Import of unlicensed medicines by individuals requires ANSM authorization in most cases
• The French approach is among the stricter in the EU for gray-market peptide access

Eastern Europe

Several Eastern European EU member states have different access patterns for specific peptides:

• Romania, Bulgaria, Russia-adjacent former Soviet states: Thymosin alpha-1 (Zadaxin in some markets) and some Russian-developed peptides (Semax, Selank, cortagen, epitalon/epithalon) are licensed medicines in Russia and some neighboring countries. These compounds are sometimes imported by EU residents with varying customs outcomes.
• Czech Republic: Historically permissive toward dietary supplements and gray-area compounds; the research chemical market has been more active domestically.
• Poland: Prescription requirements apply; some Polish compounding pharmacies have supplied peptides across borders to EU customers, a practice that has attracted regulatory attention.

Scandinavian Countries

Norway, Sweden, Denmark, and Finland generally have strict medicines regulations with close alignment to EMA standards. Norway, despite not being an EU member, closely tracks EMA guidance. Research chemical enforcement in Scandinavia has been active, and customs seizures of peptide imports are common. Prescription access through specialist physicians is available but requires demonstrating clinical need.

The Role of Research Chemical Vendors Within the EU

Several EU member states—historically including the Netherlands, Czech Republic, and some Baltic states—have hosted research chemical vendors that shipped throughout the EU. Post-2022 coordination between EU member state medicines agencies has led to more cross-border enforcement, with vendors in permissive jurisdictions increasingly receiving attention from regulators in stricter member states.

The European Medicines Agency's 2024 guidance on borderline products (compounds that may be classified as either medicines or other product categories) tightened the framework around research peptides, making it harder to operate as a research chemical supplier in countries that closely follow EMA guidance.

Practical Access in the EU

For EU residents seeking legal peptide access:

1. Consult a physician in your country who has familiarity with peptide therapy—sports medicine physicians, anti-aging specialists, or functional medicine practitioners
2. Request a named-patient or compounding prescription for the specific peptide
3. Use a licensed pharmacy in your country for dispensing; cross-border pharmacy orders within the EU are regulated under Directive 2011/62/EU

Cross-border importation from non-EU suppliers for personal use is legally complex and varies by member state. Some member states apply more discretion than others, but no EU country has an explicit personal import exemption for unlicensed research peptides from non-EU countries.

Frequently Asked Questions

Q: Is there any EU country where peptides can be bought without a prescription? No EU member state has an explicit OTC framework for therapeutic peptides of the type commonly discussed in performance or longevity contexts. Some dietary supplement-grade products (collagen peptides, bioactive peptide supplements) are sold OTC, but GHRP compounds, BPC-157, thymosin products, and similar research peptides require prescription access through physician channels in all EU member states.

Q: Can I order peptides from a US website and ship to my EU country? Customs seizure is a significant risk. EU customs authorities cooperate with national medicines regulators, and parcels identified as containing unauthorized medicines can be seized. The probability and consequences of seizure vary by country. Cross-border enforcement coordination within the EU has increased since 2022.

Q: Are Russian peptides like Semax or Selank legal in the EU? Semax and Selank are licensed medicines in Russia but do not have EMA marketing authorization or member-state national authorization in the EU. Importing them for personal use is not authorized under EU medicines law. They are available through gray-market channels in some EU countries, but seizure at customs is a real risk.

Q: Does EMA approval in one area affect availability of peptides in that class? Yes. The EMA approval of semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda) for obesity and diabetes has dramatically improved access to these GLP-1 peptides across the EU through standard prescription pathways. For peptides with no EMA-authorized representative, the off-label and compassionate use pathways are the legal alternatives.

Q: How does Brexit affect EU residents accessing UK peptides? UK-based research chemical suppliers are now outside the EU regulatory framework. Ordering from UK suppliers to EU addresses involves non-EU imports, which face EU customs review. MHRA authorization of a UK product does not confer EU authorization.

Related Articles

• Peptide Legal Status in the UK
• Peptide Legal Status in the US
• Peptide Import and Customs Guide
• FDA Peptide Regulations 2026 Update
• Are Peptides Legal? Complete US and International Guide

Track your peptide protocols and biomarker trends in Optimize.